bioAffinity Technologies, Inc. (BIAF) AI Stock Analysis

• Market Cap: $4.63M
• Dividend Yield: N/A
• Average Volume (3M): 5.91M
• Price to Earnings (P/E): ―
• Beta (1Y): -2.95
• Revenue Growth: -27.66%
• EPS Growth: 13.18%
• Country: US
• Employees: 57
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -4.74
• Shares Outstanding: 4,498,709
• 10 Day Avg. Volume: 6,249,809
• 30 Day Avg. Volume: 5,911,951
• PEG Ratio: 0.07
• Price to Book (P/B): 4.24
• Price to Sales (P/S): 1.18
• P/FCF Ratio: -1.50
• Enterprise Value/Market Cap: -0.51
• Enterprise Value/Revenue: -0.35
• Enterprise Value/Gross Profit: -1.45
• Enterprise Value/Ebitda: 0.17
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -8.1
• Revenue Forecast (FY): $7.31M

• Rating: 45 Neutral
• Price Target: $1.00 ▼(-22.48% Downside)
• Action: Reiterated Date: 02/03/26
• Date: Action: Reiterated 02/03/26

The score is held down primarily by weak financial performance (declining revenue, large losses, very negative ROE, and negative operating cash flow). Technicals also lean bearish (below moving averages and negative MACD). Positive corporate updates (CAP accreditation and CyPath® Lung traction) and the lack of a meaningful P/E due to losses provide only limited offset.

Positive Factors

CAP accreditation supporting lab quality

Maintaining College of American Pathologists accreditation is a durable quality credential for clinical labs. It reduces regulatory and operational risk, bolsters trust with physicians and health systems, and strengthens contractual and reimbursement discussions over months to years.

Strong clinical performance of CyPath® Lung

High sensitivity and specificity provide a structural clinical advantage for CyPath® Lung versus less accurate diagnostics. Persistent diagnostic accuracy supports physician adoption, guideline consideration, and durable differentiation that aids long-term commercial penetration and payer conversations.

Demonstrable commercial traction in test volumes

A sustained surge in test volume signals that the product is gaining acceptance among clinicians and referral pathways. Growing volumes improve lab utilization and unit economics, enabling incremental margin recovery and more predictable revenue as commercialization scales over the next several months.

Negative Factors

Declining revenue trend

Persistent top-line contraction undermines the business’ ability to cover fixed lab and commercialization costs. Continued revenue decline reduces leverage benefits from higher volumes, constrains reinvestment in sales and R&D, and makes multi-quarter recovery and scale more difficult.

Deep losses and weak operating cash flow

Severe negative margins and ongoing negative operating cash flow indicate limited internal cash generation, increasing reliance on external financing. This impairs the company's ability to fund lab capacity, marketing, and clinical initiatives, raising dilution and execution risk over the medium term.

Shareholder engagement/governance weakness

Failure to achieve a quorum at a special meeting signals weak shareholder participation and potential governance frictions. Low engagement can hamper timely approvals for strategic actions or financings, complicating capital raises or partnerships needed to support sustained commercialization.

bioAffinity Technologies, Inc. Business Overview & Revenue Model

Company Description

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.

How the Company Makes Money

bioAffinity Technologies generates revenue through multiple streams, primarily by commercializing its diagnostic and therapeutic products. This includes sales of its proprietary diagnostic tests to healthcare providers and institutions, as well as licensing agreements for its technologies to pharmaceutical companies. Additionally, the company may engage in partnerships with research institutions and biotech firms to co-develop new therapies, which can provide funding and shared revenue opportunities. Grants and funding from government and private entities for research and development projects also contribute to its earnings. Overall, the combination of product sales, licensing, and strategic partnerships forms the backbone of bioAffinity's revenue model.

bioAffinity Technologies, Inc. Financial Statement Overview

Summary

Weak fundamentals: revenue is declining (-11.77% TTM) and profitability is deeply negative (net margin -152.17% with negative EBIT/EBITDA). Leverage appears manageable (debt-to-equity 0.31), but ROE is extremely negative (-930.20%) and operating cash flow remains negative despite modest free cash flow improvement.

Income Statement

bioAffinity Technologies, Inc. has experienced a decline in revenue with a negative growth rate of -11.77% TTM, indicating challenges in maintaining sales momentum. The company also faces significant profitability issues, with a negative net profit margin of -152.17% and negative EBIT and EBITDA margins, reflecting operational inefficiencies and high expenses relative to revenue.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.31 TTM, suggesting manageable leverage. However, the return on equity is deeply negative at -930.20%, indicating that the company is not generating returns on shareholder investments. The equity ratio of 77.10% suggests a strong equity base relative to total assets, but the negative ROE is a significant concern.

Cash Flow

The cash flow statement reveals a slight improvement in free cash flow growth at 9.78% TTM, but the company still operates with negative operating cash flow, indicating cash management challenges. The free cash flow to net income ratio is slightly above 1, suggesting that the company is generating some cash relative to its net losses, but overall cash flow remains weak.

Breakdown	TTM	Mar 2025	Mar 2024	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.78M	9.36M	2.53M	4.80K	0.00	0.00
Gross Profit	1.62M	3.38M	791.62K	4.34K	-4.82K	-22.24K
EBITDA	-14.11M	-8.33M	-7.63M	-5.61M	-5.32M	-6.86M
Net Income	-14.74M	-9.04M	-7.94M	-8.15M	-6.33M	-7.27M
Balance Sheet
Total Assets	11.55M	6.51M	8.22M	12.18M	1.45M	145.60K
Cash, Cash Equivalents and Short-Term Investments	7.67M	1.11M	2.82M	11.41M	1.36M	83.11K
Total Debt	680.95K	1.50M	1.58M	251.75K	11.36M	10.01M
Total Liabilities	2.64M	3.91M	3.37M	1.14M	17.24M	15.22M
Stockholders Equity	8.90M	2.60M	4.86M	11.04M	-15.79M	-15.07M
Cash Flow
Free Cash Flow	-8.51M	-7.34M	-6.06M	-4.29M	-2.05M	-2.21M
Operating Cash Flow	-8.45M	-7.26M	-6.04M	-4.07M	-2.05M	-2.21M
Investing Cash Flow	-60.57K	-79.08K	-2.21M	-219.99K	0.00	-2.89K
Financing Cash Flow	15.42M	5.63M	-344.98K	14.34M	3.33M	1.72M

bioAffinity Technologies, Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIAF, the sentiment is Negative. The current price of 1.29 is above the 20-day moving average (MA) of 1.02, above the 50-day MA of 1.16, and below the 200-day MA of 4.66, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 46.70 is Neutral, neither overbought nor oversold. The STOCH value of 40.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIAF.

bioAffinity Technologies, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYNZ	48 Neutral	$7.35M	-0.13	―	―	―	―
BIAF	45 Neutral	$4.63M	-0.16	-245.18%	―	-27.66%	13.18%
INBS	44 Neutral	$6.86M	-0.85	-146.12%	―	3.26%	65.96%
NDRA	42 Neutral	$4.00M	-0.64	-236.34%	―	―	98.86%
ISPC	41 Neutral	$2.41M	-0.68	-296.20%	―	-67.73%	58.35%

bioAffinity Technologies, Inc. Corporate Events

bioAffinity Labs Maintain CAP Accreditation, Supporting CyPath Lung

On January 7, 2026, bioAffinity Technologies announced that its subsidiary Precision Pathology Laboratory Services in San Antonio successfully maintained its accreditation from the College of American Pathologists following a rigorous on-site inspection, reaffirming that the lab meets leading standards for quality, accuracy and patient safety. The CAP accreditation, viewed as the gold standard in laboratory quality, underpins the company’s CyPath® Lung test—designed to detect lung cancer as early as Stage 1A with clinical data showing 92% sensitivity and 87% specificity—and strengthens bioAffinity’s value proposition to physicians, health systems and partners as it seeks to grow revenue in a U.S. lung cancer diagnostics market estimated at $4.8 billion in 2024 and projected to more than double by 2034.

The most recent analyst rating on (BIAF) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Updates Village Oaks Physician Succession Agreement

On September 18, 2023, bioAffinity Technologies’ subsidiary Precision Pathology Laboratory Services consummated the acquisition of a San Antonio-based clinical anatomic and clinical pathology laboratory business from Village Oaks Pathology Services, with related governance structured through a succession agreement restricting the transfer of equity in Village Oaks’ professional entity to ensure continuity of designated physician ownership. In December 2025, Village Oaks’ sole shareholder, 77-year-old Dr. Roby P. Joyce, informed the company of his decision to transfer 100% of his equity in Village Oaks to long-serving pathologist Dr. James Humphreys, and on December 22, 2025, Village Oaks, PPLS and Dr. Humphreys entered into a new succession agreement that similarly restricts Humphreys from disposing of his equity without consent and establishes automatic transfer mechanisms and replacement procedures to maintain a qualified designated physician and preserve Village Oaks’ business operations, contracts, licenses and other rights.

The most recent analyst rating on (BIAF) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Adjourns Special Stockholder Meeting for Lack Quorum

On December 19, 2025, bioAffinity Technologies, Inc. convened but immediately adjourned a special meeting of stockholders after failing to reach a quorum, as an insufficient number of common shares were present in person or by proxy to conduct business. The special meeting has been rescheduled to reconvene on January 19, 2026, with the November 4, 2025 record date and all voting proposals unchanged, and previously submitted proxies remaining valid unless stockholders choose to alter their votes through the available proxy voting channels.

The most recent analyst rating on (BIAF) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies to Present at Cancer Roundtable

On December 3, 2025, bioAffinity Technologies announced that it will present a poster at the American Cancer Society National Lung Cancer Roundtable on December 8, 2025. The poster highlights the successful use of CyPath® Lung, a noninvasive sputum-based flow cytometry test, in identifying Stage 1A lung cancer in patients with atypical presentations. This development underscores the test’s potential to provide clarity in complex diagnostic scenarios, potentially reducing the need for invasive procedures and improving early-stage lung cancer diagnosis.

The most recent analyst rating on (BIAF) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.

bioAffinity Technologies Reports Surge in CyPath® Lung Tests

On November 5, 2025, bioAffinity Technologies announced significant growth in the volume of their CyPath® Lung tests, with October’s test volume showing a 111% increase over the 2025 monthly average. This growth reflects the increasing recognition of the test’s clinical value by physicians and the success of the company’s outreach efforts to healthcare providers. The steady adoption of CyPath® Lung is seen as a step towards changing the standard of care in early lung cancer detection.

The most recent analyst rating on (BIAF) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on bioAffinity Technologies, Inc. stock, see the BIAF Stock Forecast page.